Search Results

I’ve been thinking a lot about attribution bias lately — the reflex to explain someone’s behavior by pointing to their character instead of their circumstances. In medicine, this isn’t just a cognitive shortcut. It’s one of our favorite misdiagnoses, and it often shows up in the form of a single, damning label: the difficult patient. Two encounters from my own practice keep coming back to me. 1. “The Meanest Person I’ve Ever Met.” That was the handoff. The wife was “the meanest person I’ve ever met.” “Confrontational.” “Always angry.” “Impossible to deal with.” This is a common setup: a pre-labeled human wrapped in warning tape, delivered with the expectation that I will treat her like a hazard. But her husband was lying in an ICU bed because of a botched procedure that left him paralyzed. She was navigating trauma, grief, and a system that — because of medicolegal anxieties — had decided to keep her at arm’s length and speak around her instead of to her. Every door she knocked on had a sign that said You may enter; we will not tell you anything of substance. When I met her, I didn’t find the “meanest person.” I found a woman trying to save what was left of her life. She wasn’t hostile. She was frantic. She wasn’t aggressive. She was afraid. She wasn’t difficult. She was drowning. Nothing about her behavior was surprising once you considered the situation. 2. “Behavioral Issues” in an Incarcerated Patient The second case came wrapped in a different set of labels: “behavioral issues,” “noncompliant,” “gets angry,” “hard to talk to.” An incarcerated Black man with sickle cell disease — a combination that, in the hospital, often guarantees dehumanization from the start. He’d been spoken to over the shoulder, not face-to-face. Guards in the doorway. Clinicians darting in and out, clipboards between them and him. A patient assessed through a frame of suspicion before a single word was exchanged. So I did something radical in its simplicity: I sat down. I looked him in the eyes. I spent twenty minutes listening. He was delightful. Honest. Funny. Thoughtful. A person. The “behavioral issues” vanished the moment the assumptions did. The Failure Isn’t the Patient. It’s the Attribution. This is attribution bias at its most damaging: mistaking trauma for personality, mistaking fear for hostility, mistaking systemic failure for individual flaw. In medicine, we love tidy trait-based stories — she’s mean, he’s manipulative, they’re noncompliant — because traits feel permanent. Predictable. Containable. But traits are the least accurate predictors of behavior, especially in crisis. Most human behavior is not driven by character. It is driven by emotional state. It ’s driven by: fear pain powerlessness being unheard being dismissed being rushed being judged being visibly feared feeling unsafe All of these are situational. All of them are correctable. None of them are personality traits. Fixed Mindset Medicine vs. Growth Mindset Humanity Attribution bias is rooted in a fixed mindset: the belief that people behave the way they do because of unchangeable internal qualities. But humans are not static. Neuroscience makes this painfully clear. Our prefrontal cortex — the part that lets us reason, regulate, pause, and plan — is resource-hungry and fragile. When people are in crisis, their frontal lobes go offline and their limbic systems take the wheel. They become emotional, reactive, short-fused, protective. Not because they’re “bad” or “difficult,” but because they’re human. In other words: Behavior = situation × current state × available resources (not “behavior = personality”). A growth mindset — the belief that behavior is modifiable and context-dependent — is not a soft, feel-good philosophy. It’s a neuroscientific reality. It also makes us better clinicians. The Stories We Tell Shape the Medicine We Practice Once we label someone as “difficult,” we stop asking the essential questions: What happened to them? What are they afraid of? What do they need to feel safe? What system-level failures are shaping this interaction? And maybe the hardest one: Who would I like to be in their situation? That question alone could dismantle half of the attribution bias in our hospitals. The Truth Behind Most “Difficult Patients” If I’ve learned anything, it’s this: Patients are almost never difficult because of who they are. They are difficult because of what they’re going through —and because of how the system is treating them. Change the situation, and the behavior changes. Change the framing, and the person emerges. Change how we show up, and the whole encounter transforms. We don’t have “difficult patients.” We have difficult circumstances — and patients doing their best within them.

Two different patients. Two plasma exchange treatments. Two nurses asking me, gently and matter-of-factly, the same question: “Do you want to chase with some plasma?” Before becoming an attending, I had never heard the phrase. It wasn’t part of residency, fellowship, ASFA courses, or any protocol I’d ever followed. It certainly isn’t in textbooks. The first time someone asked me, I wondered whether this was a regional term or a long-standing tradition I’d somehow missed. What I’ve realized is that “plasma chasers” aren’t a formal practice at all—they’re a local solution to a real physiologic concern, passed down through experience rather than evidence. And once I understood that, the whole thing made much more sense. Two Encounters, Two Decisions The first patient had an endomyocardial biopsy two days before their TPE. That felt like a clear “yes.” Even a small pericardial bleed can turn into tamponade quickly, and albumin-only exchanges temporarily lower fibrinogen in exactly the wrong moment. The second patient had a chest-tube exchange two days prior. Compressible, external, and not associated with catastrophic rebleeding after 48 hours. That one was a comfortable “no.” Both decisions felt reasonable. But afterward, I found myself thinking about why the question exists in the first place — and why different centers use different rituals to manage uncertainty. Ambiguity Breeds Ritual During my PhD years, I saw how easily small rituals form in the lab. The postdoc who said you had to swirl counter-clockwise for best DNA yields. The technician who swore PCR only worked if she spun down tubes twice. The graduate student who insisted cells behaved better if passaged on Tuesdays. None of these traditions were harmful. They were simply the human response to complex systems with hidden variables. When outcomes are unpredictable and stakes feel high, it’s natural to reach for anything that offers a sense of control. Clinical medicine is no different. Apheresis has many moving parts, physiology we can’t always observe directly, and very little high-quality evidence for the fine details of practice. It’s not surprising that different institutions develop their own habits — some sound, some questionable, some simply inherited. “Plasma chasers” live right in that space. What the Survey Data Actually Tell Us Before I wrote this, I went looking for anything peer-reviewed about plasma chasers specifically. There isn’t anything — not a single survey or guideline entry. But there is  a published ASFA-linked survey (Zantek et al., J Clin Apher 2018) about hemostasis management and replacement fluid decisions. And the results were eye-opening: When a patient had major surgery just one day earlier, 8.9% of respondents still used albumin-only  replacement, a much higher percentage than I expected. For minor procedures one day prior, 49.5% used albumin-only, and 50.5% included some or all plasma. That’s about a 50/50 split. For a patient scenario with no bleeding risk, 94.7% used albumin-only. Which is still short of 100% like I expected. To me, that’s fascinating. It shows how inconsistent — and how intuitive — these decisions really are. Clinicians are already making judgment calls about post-procedure bleeding risk every day, even without formal algorithms. Plasma chasers are simply a more granular version of that same instinct: Does this patient need some factors right now? Could a small bleed matter? The Framework That Actually Makes Sense When I strip away the inherited rituals, peer pressure, institutional memory, and “this is how we do it here,” the physiologic picture becomes surprisingly straightforward. Use a plasma chaser when: The patient had an endomyocardial biopsy < 72 hours. The patient had a renal biopsy < 72 hours. There is a fresh injury in a space where even a small bleed can be dangerous before it becomes obvious. These are the scenarios where a little post-exchange factor support truly makes sense. Consider partial FFP replacement when: A patient has severe allergic reactions to plasma but still needs some factor replacement. A patient is highly citrate-sensitive, and full FFP carries risks. Use full FFP replacement when: The indication is TTP. There is active or recent major bleeding. There is a high-risk coagulopathy. Use albumin-only when: A small bleed won’t be catastrophic, such as with chest tubes, lumbar punctures, and GI biopsies. There’s no compelling reason for factor support. This framework isn’t mystical. It isn’t ritualistic. It’s just physiology, risk, and common sense. Why I’m Writing About This I’m not criticizing the practice of plasma chasers. In many ways, I admire the quiet wisdom embedded in these unofficial patterns of care. They represent clinicians trying to do the safest thing for their patients in a landscape where evidence is incomplete. But I also believe there’s value in naming the uncertainty, reflecting on it, and disentangling ritual from reasoning. I don’t think we talk enough about the gray zones in our specialty — the places where we make decisions based on physiology, pattern recognition, and a little bit of fear of the worst-case scenario. And I think there’s a kind of comfort in acknowledging that these instincts come from somewhere real. Because in the end, apheresis is full of places where the science is incomplete, and the art of medicine steps in — not as hoodoo, but as thoughtful, experience-guided care.

For years, transfusion-associated circulatory overload (TACO) has been framed as a purely hemodynamic problem — a case of too much blood, too fast.  But hemovigilance data are challenging that simplicity. A growing body of work suggests that in a significant subset of patients, TACO runs hot. Yes, fever. Not chills from contamination, not cytokine-release fever from a leukocyte-rich product, but true fever within hours of transfusion — sometimes the only obvious clue that something is wrong. And it’s not rare: recent studies suggest that 30–40 % of TACO cases involve fever, a rate higher than for allergic transfusion reactions with fever. [1- 3] Beyond Volume: A Hotter Kind of Overload Classically, TACO is defined by acute respiratory distress and hydrostatic pulmonary edema within six to twelve hours after transfusion. But the presence of fever doesn’t fit that simple model of mechanical overload. Research by Parmar et al. (2017) and others shows that these fevers aren’t linked to patient age, product age, or reaction severity — and in most cases they’re new-onset, not continuations of pre-existing fever. [1] Together with bedside biovigilance data showing inflammatory features in some TACO cases, [2 - 4] this has led to a re-imagining of the syndrome: TACO may be part hemodynamic, part inflammatory. The Two-Hit Hypothesis: Volume Meets Inflammation The two-hit hypothesis of “inflammatory TACO” frames the reaction as a meeting of two vulnerabilities: First hit: a susceptible patient — one with heart failure, renal disease, positive fluid balance, or critical illness that limits their ability to tolerate volume. Second hit: the transfusion itself, delivering not only volume but also biologically active mediators — cytokines, storage-lesion byproducts, and shifts in colloid osmotic pressure. This combination may tip the endothelium into dysfunction, increasing capillary permeability and producing pulmonary edema beyond what simple volume overload would explain. It also helps account for “hot-TACO” cases after even a single unit of blood. [2 - 4] Clinical Confusion: When “Hot-TACO” Mimics TRALI Fever blurs the lines. In a febrile, hypoxic patient post-transfusion, most clinicians first suspect TRALI or sepsis. Yet as multiple studies and the revised international case definition emphasize, [1, 3, 5] the presence of fever doesn’t exclude TACO. If there are clear hydrostatic findings — positive fluid balance, elevated BNP or NT-proBNP, echocardiographic evidence of elevated filling pressures, or improvement with diuretics — TACO should remain high on the list even when fever is present. Diagnostic Pearls: Sorting the Hot from the Heavy When TACO and TRALI overlap, these clues help steer the differential: 🕒 Timing: TACO usually develops within 6 hours, but may be delayed up to 12. TRALI is classically within 6 hours and not relieved by diuretics. 💧 Volume response: Improvement with diuretics or fluid restriction supports TACO. ❤️ BNP / NT-proBNP: Ratios > 1.5–2× pre-transfusion favor hydrostatic overload. 🫁 Chest imaging: TACO shows cardiomegaly and vascular redistribution ; TRALI typically presents with bilateral non-cardiogenic infiltrates. 🧪 Inflammatory markers: Fever alone doesn’t rule out TACO, but a marked cytokine surge (e.g., IL-8, IL-6) suggests TRALI or sepsis. Ultimately, distinguishing hot-TACO from other febrile transfusion reactions depends on pattern recognition rather than a single test. The key is to remember that not all TACO is “cold.” Sometimes, the circuit overload burns a little. References Parmar N et al. Vox Sanguinis.  2017;112(1):70-78. Andrzejewski C et al. Transfusion.  2012;52(11):2310-20. Wiersum-Osselton JC et al. Lancet Haematology.  2019;6(7):e350-e358. Bulle EB et al. Blood Reviews.  2022;52:100891. Delaney M et al. Lancet.  2016;388(10061):2825-2836.

A patient was admitted with a congestive heart failure exacerbation. Their hemoglobin was drifting downward — nothing dramatic, but enough to warrant a type and screen. The result wasn’t surprising: a known warm autoantibody. What was  surprising was the note that popped up beside it — “Requires washed RBCs.” We looked into it. The patient’s IgA level was reported as < 5 mg/dL on two separate occasions — a true, complete selective IgA deficiency. No history of anaphylactic reactions, no documentation of transfusion reactions at all. Still, the washed requirement persisted, a permanent flag carried forward through admissions like a family heirloom no one quite questioned. The Spectrum of IgA Deficiency Selective IgA deficiency is the most common primary immunodeficiency, occurring in roughly 1 in 300 people, though the term encompasses a spectrum. Many individuals have low but detectable  levels of IgA and remain entirely asymptomatic. A complete  deficiency — defined by an undetectable IgA level on at least two separate occasions — is far less common. (This definition is used by the European Society for Immunodeficiencies and the Immune Deficiency Foundation.) Only a fraction of these individuals go on to form anti-IgA antibodies, which have been implicated in allergic or anaphylactic transfusion reactions. The Rare Meets the Real The classic teaching looms large in every pathology and transfusion board prep book: the IgA-deficient patient who develops life-threatening anaphylaxis after receiving a standard blood component. But outside the exam room, this scenario is exceedingly  rare.The true incidence of anti-IgA–mediated anaphylaxis is unknown and appears extremely low. The literature contains only a handful of case reports and small series describing such reactions, mostly in patients with severe  IgA deficiency and detectable  anti-IgA antibodies [1–4]. A comprehensive review identified just 23 cases of anaphylaxis in immunodeficient patients receiving IVIG over several decades [2]. Even among those with measurable anti-IgA, many tolerate blood products and immunoglobulin infusions without incident [1]. The association between anti-IgA antibodies and anaphylaxis remains controversial — suggesting that other, still-uncharacterized modulators of immune reactivity may determine who reacts and who does not. Larger studies are needed to clarify the true risk and mechanisms [1]. In short: the event is exceptional in clinical practice. And for our particular patient — elderly, volume-sensitive, admitted for heart failure — the most likely transfusion complication would not be anaphylaxis at all, but TACO. The same physiology that brought them into the hospital also raises their risk for fluid overload if transfused. Re-examining the “Requires Washed RBCs” Reflex So where does that leave us? With vigilance, yes — but also with perspective. The patient’s risk for anaphylaxis appears theoretical, not demonstrated. Yet the “washed RBCs” flag carries real-world costs: longer wait times, product scarcity, and potential delays in care. We decided to order an anti-IgA assay to see whether we could safely lift the restriction — a small act of course-correction that might spare the patient unnecessary complexity in future transfusions. Because sometimes the best transfusion practice isn’t about adding more caveats. It ’s about knowing which ones no longer serve the patient. References Rachid R, Bonilla FA. The Journal of Allergy and Clinical Immunology.  2012;129(3):628-34. Williams SJ, Gupta S. Archivum Immunologiae et Therapiae Experimentalis.  2017;65(1):11-19. Salama A et al. Transfusion.  2004;44(4):509-11. Ahrens N et al. Clinical and Experimental Immunology.  2008;151(3):455-8.

Two weeks after a massive transfusion protocol for hemorrhagic shock, one of our patients developed profound thrombocytopenia — counts dropping to single digits despite transfusions. Each additional platelet unit seemed to make things worse, not better. Within days, she developed intra-abdominal bleeding that required surgical exploration and an open abdomen. When the post-transfusion purpura (PTP) panel came back, it revealed an alloantibody against HPA-1b — an uncommon finding, but one that instantly clarified what had happened. What Is Post-Transfusion Purpura? PTP is a rare, delayed transfusion reaction characterized by sudden, severe thrombocytopenia appearing 5–12 days after transfusion. The syndrome occurs most often in individuals who lack the common platelet antigen HPA-1a and have been previously sensitized, typically through pregnancy or prior transfusion. The most common culprit antibody is anti-HPA-1a, but antibodies to other platelet antigens — including HPA-5a, HPA-4a, HPA-3a, and rarely HPA-1b — have been described. Regardless of the specific target, the result is the same: the patient’s immune system destroys both transfused and autologous  platelets, leading to precipitous thrombocytopenia and risk of life-threatening bleeding. A Quick Detour Into HPA Genetics The HPA-1 system is defined by two alleles: HPA-1a, found in roughly 75–95% of most populations. HPA-1b, a minor allele whose frequency ranges from 10–24% in many European and Middle Eastern groups, but is <1% in East Asian populations. This population variation matters. In regions where HPA-1b is rare, like the US, compatible donors for patients with anti-HPA-1b can often be found locally, as most platelet units will be negative for HPA-1b. In the US, sourcing units for patients with anti-HPA-a1 is the reverse — the search for HPA-1b-positive, 1a-negative donors is extraordinarily difficult. Diagnosing PTP PTP should be suspected when: Severe thrombocytopenia develops 5–10 days post-transfusion, There is a paradoxical worsening  of counts after platelet transfusion, and There is no evidence of DIC, HIT, or marrow suppression. Diagnosis is confirmed by detecting platelet-specific alloantibodies in the patient’s serum — most commonly anti-HPA-1a. In this case, however, the antibody was anti-HPA-1b, underscoring that the immunologic mechanism is the same even when the target is rare. Treatment: Why IVIG Works (and Platelets Usually Don’t) The mainstay of treatment is intravenous immunoglobulin (IVIG) — typically 2 g/kg divided over 2–5 days. IVIG acts by saturating Fc receptors, blunting macrophage-mediated platelet destruction, and modulating the immune response. It leads to a platelet recovery in ~85% of reported cases, usually within several days. Plasma exchange can be considered in refractory cases or when IVIG is unavailable, though evidence is limited. What doesn’t  work well is platelet transfusion. Even HPA-matched platelets are often rapidly destroyed in the presence of circulating antibody. Their use is generally reserved for life-threatening bleeding when IVIG has failed or is contraindicated. Reports of transient benefit exist, but consistent success is rare. For long-term management, future RBC transfusions should be washed to remove residual platelets and platelet antigens, and HPA-compatible platelets should be considered to avoid re-exposure and further alloimmunization. Reflection From the Bench This case was a reminder that transfusion medicine sits at the crossroads of immunology and critical care. PTP may be rare, but when it strikes, it can upend a patient’s course and confound even seasoned teams. The irony of PTP is striking: transfused platelets meant to heal instead trigger the destruction of every platelet in circulation. But timely recognition, serologic confirmation, and early IVIG can turn the tide — and save both platelets and lives. When I called hematology with the antibody result today, they immediately pivoted to planning for HPA-matched support before the patient’s next surgery. That’s the value of diagnosis — not just knowing what went wrong, but knowing how to protect the patient the next time around.

When the phone rings mid-transfusion and the words “the patient is hypotensive”  hit your ears, there’s a short list of life-threatening reactions you can’t afford to miss. Four share a similar opening act — fever, hypotension, and sometimes respiratory distress. The fifth looks different but can end the same way if unrecognized. Here’s how to triage the call, fast. 1️⃣ Anaphylaxis Clue:  Sudden hypotension, respiratory distress, flushing, or urticaria — often within minutes  of starting the unit. Ask:  “Did the team give epinephrine?” If they didn’t, that’s step one. Stop the transfusion, keep the line open with saline, and treat per anaphylaxis protocol. Later, you’ll think about IgA deficiency and washed products — but right now, it’s airway, breathing, circulation. 2️⃣ Septic Transfusion Reaction Clue:  Fever and rigors that escalate to shock, often during or shortly after transfusion. Ask:  “Did the team send blood cultures and start antibiotics?” Stop the transfusion immediately and culture both  patient and product. Gram-negative sepsis from a contaminated platelet or red cell unit can mimic anaphylaxis in its speed. 3️⃣ TRALI (Transfusion-Related Acute Lung Injury) Clue:  New or worsening hypoxia and bilateral infiltrates within 6 hours of transfusion, without signs of circulatory overload. Ask:  “Did the oxygen saturation drop or the O₂ requirement go up?” If yes, order a chest X-ray. This is non-cardiogenic pulmonary edema — no diuretics, no fluids, just supportive care and notification to the blood bank. 4️⃣ Acute Hemolytic Transfusion Reaction (AHTR) Clue:  Fever, flank or back pain, hypotension, dark urine, or a sudden rise in bilirubin. Ask:  “Can you send a DAT and haptoglobin?” This one’s about clerical error until proven otherwise. Check patient and unit IDs, call the blood bank, and prepare for aggressive hydration to protect the kidneys. 5️⃣ TACO (Transfusion-Associated Circulatory Overload) Clue:  Hypertension, dyspnea, pulmonary edema, elevated BNP — usually in patients with limited cardiac reserve. Ask:  “Did the team give diuretics, and did the patient respond?” Unlike TRALI, TACO should  improve with diuresis. Prevention is key: slow rates, split units, pre-dose furosemide when indicated. 🩸 Putting It All Together Reaction BP Trend Fever Resp Distress Key Test / Treatment Anaphylaxis ↓ ± + Epinephrine Septic ↓ + ± Cultures + Antibiotics TRALI ↓ ± + CXR → Non-cardiogenic edema AHTR ↓ + ± DAT / Haptoglobin TACO ↑ – + Diuretics → Improves Bottom line: When every minute matters, think pattern-recognition first, paperwork later. Five questions can save a life — and keep you calm when the call comes in.

Every so often a case comes along that refuses to fit into our tidy categories. An adult male presented to the emergency department with profound weakness and striking jaundice. His hemoglobin was 3.7 g/dL, yet he was mentating normally and his lactate was within range — clear evidence of physiologic compensation. The chemistry panel featured a total bilirubin >70 mg/dL, direct fraction ≈ 40 mg/dL, with biliary dilation on CT abdomen/pelvis. On the hematology side, LDH was elevated, haptoglobin undetectable, and the antibody screen revealed a warm autoantibody. Parsing the Pattern At first pass, this looks like hemolysis. Severe anemia, high indirect bilirubin, low haptoglobin, elevated LDH — all the hallmarks are there. But a direct fraction comprising more than half the total complicates the picture: pure hemolysis shouldn’t yield that much conjugated bilirubin. That left two possibilities running in parallel: Primary biliary obstruction (choledocholithiasis, mass, or stricture). Secondary cholestasis from sustained hemolytic load — the liver overwhelmed by the ongoing destruction and turnover of red cells. The patient’s stability pointed toward chronicity. A hemoglobin of 3.7 g/dL with preserved mentation doesn’t happen overnight. This was the physiology of slow, compensated hemolysis finally tipping into hepatic decompensation. Hemolysis Meets Cholestasis In warm autoimmune hemolytic anemia (AIHA), extravascular destruction can be relentless but insidious. Over weeks to months, bilirubin production rises and the liver adapts — upregulating conjugation and secretion. Eventually, canalicular transport capacity becomes the rate-limiting step. The bile becomes supersaturated with bilirubin diglucuronide, predisposing to pigment stone formation and sometimes true biliary obstruction. At that point, the chemistry shifts: direct hyperbilirubinemia emerges, not because the process stopped being hemolytic, but because the liver and biliary tree have been drawn into the downstream pathology. The biliary dilation on CT fits perfectly — not as a primary obstruction, but as a secondary phenomenon of chronic pigment overload. Testing in Context The serologic workup tied it together. Positive DAT with warm autoantibody → ongoing immune hemolysis. Elevated LDH and absent haptoglobin → hemolytic physiology confirmed. Normal lactate and preserved mental status → chronic compensation. The picture that emerged was not an acute biliary event but chronic AIHA complicated by secondary cholestasis, possibly with choledocholithiasis from pigment stones. Biliary Workup MRCP revealed subtle hilar ductal thickening, raising concern for an underlying cholangiocarcinoma. Yet the broader picture didn’t cooperate: tumor markers and an autoimmune cholangiopathy panel were unremarkable. To clarify, an ERCP was performed — several darkly pigmented stones were extracted, and brushings of the bile duct were sent for cytology. No malignant cells were identified. The findings reinforced the idea of secondary  biliary involvement rather than a primary neoplasm. The obstruction appeared mechanical but self-limited, the likely consequence of pigment stone formation in the setting of chronic hemolysis. It was a reminder that when the biliary tree becomes the downstream casualty of hematologic disease, imaging can mimic malignancy and tumor markers can mislead. Takeaway This case reminds me how rarely biology stays within our categorical lines. Direct hyperbilirubinemia does not exclude hemolysis when destruction has been sustained enough to overwhelm excretory capacity. It’s the intersection we rarely see illustrated in textbooks: where hemolysis becomes overwhelming, the liver becomes a bottleneck, and “prehepatic” injury evolves into a mixed cholestatic picture. Sometimes the right answer really is “both.”

The patient was a premature infant, six weeks old and just 2.5 kilograms, already on ECMO for primary cardiopulmonary failure. Sepsis developed secondarily, and the critical-care team requested plasmapheresis for a presumed cytokine storm — a Category III indication  under the current ASFA guidelines. On paper, the rationale made sense. But when I calculated the total blood volume — only 250 mL  (≈ 100 mL/kg for a premature infant) — it was immediately clear this baby was too small for the machine. The Terumo technical support representative confirmed the following minimum specifications  for therapeutic plasma exchange: 30 cm:  Minimum height the system can accept 2 kg:  Minimum weight the system can accept 300 mL:  Minimum total blood volume (manual entry) 10 %:  Minimum hematocrit 0.5 L:  Minimum plasma volume (machine default = 1.0 L) 25 kg:  Minimum weight for automatic TBV calculation Despite meeting the weight requirement, the patient’s total blood volume was below the system’s operational threshold. The procedure was simply not possible. After discussing options with the ICU team, we recommended whole blood exchange  instead — a technically feasible alternative that allowed for cytokine and toxin removal within the constraints of neonatal physiology. This case underscored an important reality: sometimes the limits we face are not physiologic but mechanical. Even when a treatment is conceptually justified, our instruments may not yet be scaled to our smallest and most fragile patients. Until apheresis technology evolves to meet neonatal demands, these moments will remain a quiet reminder that innovation in transfusion medicine isn’t only about what  we can do — it’s also about who  we can safely do it for.

The antibody screen looked straightforward at first glance — an O positive patient with apparent anti-D reactivity in plasma. But the autocontrol was positive, and the eluate was a panagglutinin. Those two results change the entire story. Working the Differential When a D-positive patient’s plasma reacts like anti-D, the immediate differentials are familiar: Partial D variant (missing epitope exposure) Passive anti-D (recent RhIg or IVIG) Autoantibody with apparent Rh specificity Each of these has a characteristic fingerprint. A partial D can produce alloanti-D, but that’s rare in a serologically D-positive person without prior exposure, and the eluate would mirror the plasma pattern, not broaden to panreactivity. Passive anti-D behaves cleanly: plasma reacts like anti-D, eluate is negative or weakly specific, and there’s a clear administration history. What we had was different: a positive autocontrol and a panreactive eluate.That combination eliminates the first two possibilities. The reactivity isn’t alloimmune or passive — it’s autoimmune. The Testing Trail The workup unfolded in layers: Antibody screen — positive with a D-like pattern. Antibody identification panel — strengthened reactivity with D-positive cells, weaker or negative with D-negative cells, suggesting “anti-D.” Autocontrol — positive, establishing that the antibody also reacts with the patient’s own RBCs. Elution study — recovered antibody from patient RBCs showed panreactivity  against all reagent cells. That last result is the pivot point. When an eluate reacts with every cell tested, regardless of Rh type, it means the antibody bound in vivo is not truly D-specific. It’s reacting broadly, most often with epitopes shared across the Rh complex. The apparent anti-D in plasma was the “tip” of the reaction spectrum; concentrating the antibody in the eluate revealed its full range. Understanding the Mechanism This pattern — an apparent anti-D that becomes panreactive on elution — is classic for autoantibodies with relative Rh specificity. Several studies have shown that the Rh complex is a common autoantigenic target in warm AIHA. Barker et al. demonstrated that autoantibodies from AIHA patients could immunoprecipitate Rh-associated polypeptides, confirming that these antibodies truly interact with the Rh complex [1].Later, Iwamoto et al. mapped this reactivity to extracellular peptide loops of Rh antigens (RhD, cE, ce, CE), showing that the apparent specificity stems from how these antigens share structural epitopes [2]. That explains why plasma reactivity can look D-restricted — the antibody’s affinity may be stronger for cells expressing D — but once concentrated, the cross-reactivity becomes universal. Issitt and Pavone and later Henry et al. described this as the “false specificity” of Rh-directed autoantibodies: antibodies that seem to be anti-D, anti-e, or anti-C but are actually targeting shared determinants like Hr, Hro, or Rh34 [3,4]. Clinical Handling In this case, the patient had no evidence of hemolysis and was evaluated in the outpatient setting for routine pretransfusion testing. We were able to rule out any underlying alloantibodies on the work up, and when transfusion was later anticipated, we selected a D-negative unit out of caution. The transfusion was uneventful — confirming that the pattern was serologic, not pathologic. Why It Matters The take-home message isn’t about the D antigen at all — it’s about pattern recognition in serology . When plasma looks specific but the eluate doesn’t, the specificity is probably illusionary. The positive autocontrol and panagglutinin eluate are the signposts pointing away from alloimmunization and toward autoimmunity — specifically, Rh-complex targeting. In documentation, this deserves clarity: “Warm autoantibody with apparent anti-D specificity. Eluate panreactive. No evidence of alloanti-D.” It’s a small notation that prevents a future technologist from re-investigating a mystery that isn’t one — and prevents a clinician from worrying about sensitization that never occurred. References Barker JE et al. J Clin Invest.  1989;84(3):1010–1015. Iwamoto S et al. Blood.  1995;86(1):341–348. Issitt PD, Pavone B. Transfusion.  1978;18(6):702–708. Henry SM et al. Vox Sang.  1987;52(3):193–198.

1 | Finding the rhythm of replacement When people talk about plasma exchange, they usually focus on what  to replace. Less often discussed is how often  we can safely do it. Frequency determines not just antibody clearance but also coagulopathy, albumin balance, and overall tolerance. Replacement fluid and schedule are inseparable — each constrains the other. 2 | Albumin kinetics – recovery and depletion Each 1.0 plasma-volume exchange removes roughly 60–70 % of circulating proteins, albumin included.The liver replaces about 15–20 grams of albumin per day, enough for partial recovery in 24 hours but not full repletion until three to five days later. Even when using 5 % albumin as the replacement fluid, the patient remains in negative protein balance. The solution restores volume and some oncotic pressure , but not total protein mass . Studies have shown that after several consecutive exchanges, even when spaced 48 hours apart, serum albumin and total protein falls. Patients can develop dependent edema or fatigue — subtle, cumulative signs of depletion. 3 | Coagulation factors – the real rate-limiter Albumin replacement also removes the clotting proteins that plasma would otherwise supply. Each albumin-only exchange removes about 60% of plasma fibrinogen, and hepatic synthesis restores only about 60% of that loss over 48 hours. Two daily albumin exchanges in a row can easily drive fibrinogen below 100 mg/dL, the level where bleeding risk becomes clinically relevant. While daily TPE with albumin is generally avoided, logistics can sometimes demand it. Fibrinogen should be checked after two daily albumin TPEs. If it’s low and further daily therapy is unavoidable, switch part or all of the replacement to plasma. For isolated hypofibrinogenemia in an otherwise stable patient, cryoprecipitate can be given instead of altering the entire replacement plan. Plasma-based replacement (as in TTP) sidesteps this issue entirely, because it replenishes what’s removed. 4 | Antibody redistribution – why spacing matters Only about half of circulating IgG lives in the vascular space. The rest resides in tissues and slowly diffuses back into plasma over 12–24 hours. Performing exchanges too close together means removing replacement albumin before those extravascular antibodies re-equilibrate. Spacing sessions every 48 hours allows the newly mobilized antibody pool to enter plasma, improving clearance efficiency and reducing unnecessary protein loss. It also coincides neatly with the time course of fibrinogen recovery — physiology and pharmacokinetics in agreement. 5 | Typical schedules by indication Indication Type Replacement Fluid Frequency Physiologic Rationale TTP / ADAMTS13 deficiency 100 % FFP Daily until platelet recovery Enzyme repletion + inhibitor removal outweigh coagulopathy risk GBS / MG / NMO 100 % albumin Every 48 h × 5 exchanges Allows antibody re-equilibration + fibrinogen recovery ANCA / anti-GBM vasculitis Albumin ± plasma Daily × 2–3 → every 48 h Balances clearance against factor depletion Chronic or maintenance TPE Albumin ± ≤ 30 % crystalloid 2–3 × per week Prevents cumulative protein loss 6 | Clinical guardrails Monitor fibrinogen, albumin, and ionized calcium at baseline and every two to three sessions. Avoid albumin-only exchanges within 24 hours of any invasive procedure. If fibrinogen < 100 mg/dL, add plasma or give cryo before proceeding. Remember that “daily” in published series often means weekdays only  — those weekend pauses are physiologic recovery periods in disguise. 7 | Takeaway Replacement composition and timing aren’t separate decisions. Albumin-only exchanges can safely run for two consecutive days if unavoidable, but beyond that, coagulopathy becomes the constraint. For autoimmune antibody disorders, an every-other-day rhythm improves efficiency and safety. For plasma-dependent disorders such as TTP, daily plasma exchanges remain essential until the disease turns the corner. The rhythm of plasma exchange isn’t set by habit or scheduling convenience — it’s written in the half-lives of the proteins we remove and the ones the body must rebuild.

1 | A brief historical arc In the early years of therapeutic plasma exchange (TPE), replacement was simple: plasma when coagulation factors were needed, 5 % albumin when they were not. Through the 1980s and 1990s, a few groups began experimenting with albumin–saline mixtures to stretch resources and probe the physiology of volume replacement. The results were instructive. Larger saline fractions consistently lowered oncotic pressure, triggered transient hypotension, and produced mild metabolic acidosis. By the late 1990s, most centers had returned to albumin-dominant replacement, reserving plasma for specific indications and using small amounts of crystalloid only for circuit priming, rinseback, or minor volume adjustments. 2 | The physiology — why saline isn’t “neutral” Oncotic pressure: Albumin preserves intravascular volume; saline does not. When saline replaces plasma in large proportions, intravascular volume can fall even as total volume looks adequate. Chloride load and acid–base balance: 0.9 % NaCl carries 154 mmol/L of chloride and a strong-ion difference of 0, which drives hyperchloremic metabolic acidosis. Balanced crystalloids such as Lactated Ringer’s and Plasma-Lyte A include buffers (lactate, acetate, gluconate) and have positive SIDs, making them acid–base neutral or mildly alkalinizing. Renal perfusion: Hyperchloremia activates the macula densa and causes afferent arteriolar constriction, reducing glomerular filtration. That link between chloride load and renal perfusion is one reason large critical-care trials now favor balanced crystalloids over saline. 3 | Guidelines in brief ASFA 2023: Albumin and plasma remain the mainstays. Crystalloids appear only in technical notes, usually as minor adjuncts. Canadian Blood Services: “The most commonly used replacement fluid is 5 % albumin… some centres also use normal saline in combination with albumin or plasma, though this practice is increasingly uncommon.” AJKD Nephrology Core Curriculum 2023: For cost containment, mixtures such as 80:20 albumin:saline are acceptable, with a practical upper limit around 30 % crystalloid. Across documents, the message is consistent: albumin for most indications, plasma when factors are needed, and crystalloids only in modest proportion. 4 | How crystalloids are used today Default:  100 % 5 % albumin for non-factor indications. Plasma:  for TTP and other settings requiring factor repletion. Crystalloids:  used mainly for circuit priming and rinseback, ≤ 20–30 % of the replacement volume when cost or volume considerations apply, and preference for balanced crystalloids over saline to avoid chloride-driven acidosis. Why not more saline? Beyond small fractions, you gain nothing physiologically and risk hyperchloremic acidosis, hypotension, and renal stress — all without oncotic support. 5 | Takeaway Crystalloids do have a place in TPE — but it’s a supporting role. The foundation remains albumin, with plasma added when coagulation factors are required. When crystalloids are used, keep them to no more than about one-third of the exchange volume and choose balanced solutions like Plasma-Lyte A or Lactated Ringer’s whenever possible. It’s a small composition detail in a large-volume therapy — but over several liters, those chloride ions and milliequivalents of buffer can make a measurable difference.

The Overlooked Half of the Exchange When we talk about plasma exchange, most of the conversation centers on what we’re removing — antibodies, paraproteins, cytokines. But replacement fluid is the other half of the equation. It must maintain intravascular volume and oncotic pressure, and sometimes also return essential plasma proteins like clotting factors. Choosing the right replacement fluid is one of the most important clinical judgments in apheresis. It affects safety, hemostasis, and the overall trajectory of a patient’s recovery far more than most order sets acknowledge. The Options Menu Fluid What It Brings When It Shines Notes 5% Albumin Volume and oncotic pressure Stable autoimmune or neurologic diseases May worsen bleeding risk if used early post-op or in coagulopathic patients; lacks clotting factors and immunoglobulins. Fresh Frozen Plasma (FFP) Coagulation factors, fibrinogen, and volume TTP, pre- and early post-transplant desensitization, active bleeding or bleeding diathesis, coagulopathy Risk of allergic reactions, TRALI, volume overload; slower thaw-to-infusion logistics. Cryo-poor Plasma Volume replacement with reduced fibrinogen Refractory TTP Rarely used; availability limited. Saline (adjunct) Volume expander Used with albumin for partial replacement Can dilute plasma proteins if overused; typically limited to ≤20–25 % of total replacement volume. Combination strategies: A 50 : 50 replacement can balance safety and practicality. Always run the fluid you want to “stick around" at the end of the procedure. For saline : albumin , run albumin last. For albumin : FFP , run FFP last. Clinical Scenarios — Matching the Fluid to the Patient TTP: 100 % FFP. You’re replacing the very factors the patient lacks, especially ADAMTS13 and other coag proteins essential for recovery. Transplant-related Apheresis: Desensitization:  Use FFP before transplant and generally for 1–2 weeks post-transplant, depending on stability and laboratory values (fibrinogen, platelets, INR). Antibody-Mediated Rejection (AMR) Post-Transplant:  Replacement choice depends on time since surgery and concurrent risks. In early rejection with bleeding risk, use FFP; later or stable cases can transition to albumin or a mix. Other Antibody-Mediated Diseases (e.g., MG, CREST, etc.): Albumin is typically adequate. However, for syndromes with vasculopathy or active bleeding (such as diffuse alveolar hemorrhage), use FFP until bleeding risk resolves. Liver Failure or DIC: Therapeutic plasma exchange in these settings is uncommon and typically limited to specialized protocols (for example, acute liver failure with hyperammonemia or toxin removal). When performed, FFP is used to replace lost function and mitigate coagulopathy. Myths & Misconceptions “Albumin is always safer.” Not when coagulation support is needed — context determines risk. “FFP is only for TTP.” It’s also indicated when hemostatic balance is fragile, such as peri-transplant or with bleeding vasculopathies. “Replacement fluid choice doesn’t matter.” It quietly dictates post-procedure stability, especially in surgical and critically ill patients. The Quiet Art of Replacement Replacement fluid selection looks mundane on paper, but it’s where clinical judgment lives. It’s the difference between doing an exchange and doing it wisely. Protocols provide the framework; experience fills in the nuance — knowing when to mix, when to taper, and when to pivot from albumin to plasma because the numbers (or the drain output) tell you to. In apheresis, the machines may be automated, but judgment isn’t. The fluid you choose — and the order you run it — still depends on the most analog tool we have: your brain.